LOXO Loxo Oncology, Inc.

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that company management will participate in fireside chats at the following upcoming investor conferences:

• Citi Annual Biotech Conference in Boston on September 5, 2018 at 8:45 a.m. ET
• Morgan Stanley Global Healthcare Conference in New York City on September 13, 2018 at 9:10 a.m. ET

Live webcasts of the fireside chats will be available at http://ir.loxooncology.com/.

About Loxo Oncology Loxo Oncology is a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, with the intention of delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:Lauren CohenDirector, Corporate Communicationslcohen@loxooncology.com

Investors:Peter RahmerEndurance Advisors, LLC415-515-9763prahmer@enduranceadvisors.com

Media:Dan Budwick1AB Media973-271-6085dan@1abmedia.com